← Back to Screener
Evotec SE American Depositary Shares (EVO)
Price$2.80
Value ScoreC
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-21.46%
Price vs S&P 500 (4W)-5.14%
VGM Score43.08
Market Capitalization$1.05B
All Metrics
P/CF (Annual)45.82x
Book Value / Share (Quarterly)$4.55
P/TBV (Annual)1.24x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)1.61%
Cash Flow / Share (Quarterly)$-0.34
Price vs S&P 500 (YTD)-16.86%
Gross Margin (TTM)11.47%
Net Profit Margin (TTM)-26.02%
EPS (TTM)$-1.26
10-Day Avg Trading Volume0.60M
EPS Excl Extra (TTM)$-1.26
Revenue Growth (5Y)9.49%
EPS (Annual)$-0.67
ROI (Annual)-8.21%
Gross Margin (Annual)14.49%
Net Profit Margin (5Y Avg)-7.40%
Cash / Share (Quarterly)$3.02
Revenue Growth QoQ (YoY)-21.67%
ROA (Last FY)-6.04%
Revenue Growth TTM (YoY)-5.48%
EBITD / Share (TTM)$-1.03
ROE (5Y Avg)-7.99%
Operating Margin (TTM)-21.15%
Cash Flow / Share (Annual)$-0.60
P/B Ratio1.30x
P/B Ratio (Quarterly)1.09x
Net Income / Employee (Annual)$-26,252
EV / Revenue (TTM)1.22x
Net Interest Coverage (TTM)-6.37x
ROA (TTM)-11.18%
EV / EBITDA (TTM)34.11x
EPS Incl Extra (Annual)$-0.67
Current Ratio (Annual)2.07x
Quick Ratio (Quarterly)1.50x
3-Month Avg Trading Volume0.86M
52-Week Price Return-31.10%
Revenue / Employee (TTM)$189,202
Tangible BV / Share (Quarterly)$2.57
P/S Ratio (Annual)1.15x
Asset Turnover (Annual)0.46x
52-Week High$7.84
Operating Margin (5Y Avg)-4.57%
EPS Excl Extra (Annual)$-0.67
CapEx CAGR (5Y)-3.57%
Tangible BV CAGR (5Y)4.54%
26-Week Price Return-13.53%
Quick Ratio (Annual)1.96x
13-Week Price Return-12.74%
Total Debt / Equity (Annual)0.55x
Current Ratio (Quarterly)1.68x
Enterprise Value$1.05B
Revenue / Share Growth (5Y)6.38%
Asset Turnover (TTM)0.43x
Book Value / Share Growth (5Y)0.71%
Revenue / Employee (Annual)$200,305
Inventory Turnover (Annual)22.31x
Pretax Margin (Annual)-11.01%
Cash / Share (Annual)$3.24
3-Month Return Std Dev61.80%
Gross Margin (5Y Avg)19.80%
Net Income / Employee (TTM)$-49,267
EBITDA Interim CAGR (5Y)20.02%
ROE (Last FY)-12.72%
Net Interest Coverage (Annual)-11.10x
EPS Basic Excl Extra (Annual)$-0.67
P/FCF (TTM)17.89x
Receivables Turnover (TTM)4.20x
Total Debt / Equity (Quarterly)0.55x
EPS Incl Extra (TTM)$-1.26
Receivables Turnover (Annual)4.83x
ROI (TTM)-15.70%
P/S Ratio (TTM)1.22x
Pretax Margin (5Y Avg)-5.56%
Revenue / Share (Annual)$5.13
Tangible BV / Share (Annual)$5.10
Price vs S&P 500 (52W)-55.46%
Year-to-Date Return-9.50%
5-Day Price Return-7.03%
EPS Normalized (Annual)$-0.67
ROA (5Y Avg)-3.63%
Net Profit Margin (Annual)-13.13%
Month-to-Date Return-6.59%
EBITD / Share (Annual)$-0.05
Operating Margin (Annual)-7.13%
LT Debt / Equity (Annual)0.24x
P/CF (TTM)48.56x
ROI (5Y Avg)-5.22%
LT Debt / Equity (Quarterly)0.43x
EPS Basic Excl Extra (TTM)$-1.26
P/TBV (Quarterly)1.94x
P/B Ratio (Annual)1.19x
Inventory Turnover (TTM)19.84x
Pretax Margin (TTM)-24.04%
Book Value / Share (Annual)$5.30
Price vs S&P 500 (13W)-20.99%
Beta1.84x
P/FCF (Annual)37.16x
Revenue / Share (TTM)$4.85
ROE (TTM)-24.55%
52-Week Low$4.00
vGradeC
gGradeD
mGradeD
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.92
3.85
3.85
3.75
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EVOEvotec SE American Depositary Shares | C | D | D | $2.80 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Evotec is a drug discovery and contract development and manufacturing organization (CDMO) that partners with pharmaceutical, biotechnology, and academic organizations across multiple therapeutic areas including oncology, central nervous system disorders, and infectious diseases. The company operates through two main segments: Shared R&D services (approximately 80% of revenue), which provides drug discovery, development, and manufacturing on both fee-for-service and collaboration-based models, and Just-Evotec Biologics (approximately 20% of revenue), which offers CDMO services for biologics. With over 5,000 employees and 18 production sites across Europe and the United States, Evotec serves as an integrated partner throughout the drug development lifecycle.